Chinese Medicine Regulates Ferroptosis to Treat Lung Cancer:A Review
This article provides a systematic review of the research progress in the mechanisms related to lung cancer and ferroptosis,ferroptosis-related lung cancer biomarkers and gene mutation targets,and ferroptosis-targeted regulation of Chinese medicine in treating lung cancer in the past five years,providing a feasible and effective basis for the prevention and treatment of lung cancer with Chinese medicine and the development of new drugs.According to the available studies,ferroptosis is widely suppressed in lung cancer,while the specific regulatory mechanisms have not been fully elucidated.The suppression is related to lipid metabolism,iron metabolism,cystine/glutamate antiporter system Xc-(System Xc-)/glutathione(GSH)/glutathione peroxidase 4(GPX4),ferroptosis suppressor protein 1(FSP1)/coenzyme Q10(CoQ10)/nicotinamide adenine dinucleotide phosphate[NAD(P)H],long non-coding RNA(lncRNA),nuclear factor E2-related factor 2(Nrf2),and p53.In modern times,traditional Chinese medicine is widely used in the comprehensive treatment of lung cancer,and it has gradually become a hot research topic due to its obvious advantages of anti-tumor activity,high efficacy,and low toxicity.Traditional Chinese medicine plays an important role in the treatment of lung cancer.Studies have shown that the active components,extracts,and prescriptions of Chinese medicine can induce ferroptosis in lung cancer cells through targeted regulation of iron metabolism,lipid metabolism,and p53,Nrf2,LncRNA,and GPX4 pathways to inhibit the growth and proliferation of lung cancer,thus exerting anti-tumor effects.Therefore,regulating ferroptosis is expected to become a new direction for preventing lung cancer.Basic research has shown that Chinese medicine can regulate ferroptosis via multiple targets and pathways in the treatment of lung cancer.At present,Chinese medicine demonstrates great research prospects in regulating ferroptosis to treat lung cancer,which,howeve,still faces challenges to achieve clinical transformation.